Hemangioma

Parvovirus vector delivers antiangiogenic IP-10 to suppress vascular tumors

Published in Gene Therapy Weekly, June 6th, 2002

by Sonia Nichols, senior medical writer - IP-10 gene therapy is useful for reducing the size of highly vascular tumors, researchers in Europe report.

IP-10 is an antiangiogenic chemokine. When expressed by the parvovirus MVMp, the novel gene therapy MVMp/IP-10 diminishes the size of tumors implanted into mice with competent immune systems. The investigators, who work at major research institutes in Germany and Italy, believe that by extrapolation comparable gene therapy delivered by parvoviruses would reduce the size of highly vascular tumors in humans.

"Intratumoral/intraperitoneal administration of only 3x10⁷ replication units of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2002-06-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry